908 Devices Inc. (NASDAQ:MASS) CFO Sells $23,952.24 in Stock

908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith sold 10,236 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $2.34, for a total transaction of $23,952.24. Following the completion of the transaction, the chief financial officer now owns 109,870 shares of the company’s stock, valued at approximately $257,095.80. This trade represents a 8.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

908 Devices Stock Performance

NASDAQ MASS opened at $2.37 on Wednesday. The stock’s 50 day simple moving average is $2.35 and its 200-day simple moving average is $3.27. 908 Devices Inc. has a 1-year low of $1.81 and a 1-year high of $7.91.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its holdings in shares of 908 Devices by 14.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock worth $765,000 after buying an additional 28,015 shares in the last quarter. Geode Capital Management LLC boosted its position in 908 Devices by 1.2% during the third quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock worth $1,970,000 after acquiring an additional 6,634 shares during the last quarter. Millennium Management LLC boosted its position in 908 Devices by 35.5% during the second quarter. Millennium Management LLC now owns 618,310 shares of the company’s stock worth $3,184,000 after acquiring an additional 161,922 shares during the last quarter. State Street Corp grew its stake in 908 Devices by 1.2% during the 3rd quarter. State Street Corp now owns 479,044 shares of the company’s stock valued at $1,662,000 after acquiring an additional 5,704 shares in the last quarter. Finally, Barclays PLC raised its holdings in 908 Devices by 452.7% in the 3rd quarter. Barclays PLC now owns 46,214 shares of the company’s stock valued at $160,000 after acquiring an additional 37,853 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MASS shares. Stephens restated an “overweight” rating and issued a $6.00 price target on shares of 908 Devices in a research note on Wednesday, January 15th. Leerink Partnrs downgraded 908 Devices from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 908 Devices in a research report on Saturday. Leerink Partners reissued a “market perform” rating and issued a $4.00 price target (down previously from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Finally, Stifel Nicolaus decreased their price objective on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.